Who
Joseph Ciaffoni
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Indivior Pharmaceuticals; President and CEO, Collegium Pharmaceutical; President, U.S. Branded Pharma, Endo International.
In numbers
- Trades disclosed
- 127
- Buys
- 0
- Sells
- 31
- Bought
- $0
- Sold
- $16.9M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 16 Aug 2016
- Last trade
- 22 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 23 Jun 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —1,266,903 | filing |
| 22 Jun 2026filed 23 Jun 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $23.5M612,549 at $38.32 | filing |
| 22 Jun 2026filed 23 Jun 2026 | INDV Indivior Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,266,903 | filing |
| 22 Jun 2026filed 23 Jun 2026 | INDV Indivior Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,266,903 | filing |
| 22 Jun 2026filed 23 Jun 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —1,266,903 | filing |
| 22 Jun 2026filed 23 Jun 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code F | $23.5M612,549 at $38.32 | filing |
| 10 Feb 2026filed 12 Feb 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —79,976 at $0.00 | filing |
| 10 Feb 2026filed 12 Feb 2026 | INDV Indivior PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —79,976 at $0.00 | filing |
| 12 Feb 2024filed 14 Feb 2024 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —119,000 at $0.00 | filing |
| 12 Feb 2024filed 14 Feb 2024 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code A | —179,734 at $0.00 | filing |
| 12 Feb 2024filed 14 Feb 2024 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code F | $1.6M47,445 at $33.70 | filing |
| 12 Feb 2024filed 14 Feb 2024 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code F | $2.7M81,422 at $33.70 | filing |
| 21 Dec 2023filed 22 Dec 2023 | COLL Collegium Pharmaceuticaloption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,357 at $0.00 | filing |
| 21 Dec 2023filed 22 Dec 2023 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code M | $93K4,357 at $21.34 | filing |
| 21 Dec 2023filed 22 Dec 2023 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Sold | $132K4,357 at $30.38 | filing |
| 20 Dec 2023filed 20 Dec 2023 | COLL Collegium Pharmaceuticaloption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —26,454 at $0.00 | filing |
| 20 Dec 2023filed 20 Dec 2023 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code M | $565K26,454 at $21.34 | filing |
| 20 Dec 2023filed 20 Dec 2023 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Sold | $804K26,454 at $30.40 | filing |
| 19 Dec 2023filed 20 Dec 2023 | COLL Collegium Pharmaceuticaloption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,516 at $0.00 | filing |
| 19 Dec 2023filed 20 Dec 2023 | COLL Collegium PharmaceuticalPharmaceuticals | SEC FORM 4 Code M | $310K14,516 at $21.34 | filing |
News
Head to Head Survey: Collegium Pharmaceutical (NASDAQ:COLL) versus Journey Medical (NASDAQ:DERM)COLL · dailypolitical.com · 22 Oct 2026Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Stock Has Consensus Price Target of $48.71COLL · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name Joseph Ciaffoni; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.